MetaCap

Aquestive Therapeutics (AQST) vs CorMedix (CRMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aquestive Therapeutics (AQST) has outperformed CorMedix (CRMD) over the past year, losing 39.5% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -45.7% for AQST. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $419.2 million), about 1.0 times the size, while CorMedix is growing revenue faster (+617.0% vs -22.6%).

CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -188.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AQST-39.51%CRMD-45.56%
+36%-11%-58%
Nov 21, 20251 yearNov 20, 2026
AQST-42.04%CRMD+2.73%
+203%+50%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AQST versus CRMD key metrics
MetricAQSTCRMD
Share price$3.46$5.27
Market cap$434.88M$419.16M
1-day change-6.61%+3.74%
YTD return-46.44%-54.69%
1-year return-39.51%-45.56%
5-year return-45.68%+3.94%
P/E ratio (TTM)—8.23
Forward P/E—15.06
EPS (TTM)$-0.65$0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.55M$311.71M
Revenue growth (YoY)-22.61%+617.03%
Net income (latest FY)$-83.78M$163.06M
Gross margin58.35%88.46%
Operating margin-159.50%48.17%
Net margin-188.09%52.31%
52-week high$6.74$13.02
52-week low$2.93$4.47
Distance from 52-week high-48.63%-59.52%
Analyst consensusstrong_buybuy
Avg. price target upside+169.65%+161.86%
Average volume2.41M1.44M
Shares outstanding125.69M79.54M
Employees147191
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -188.1 cents for Aquestive Therapeutics.
  • CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -22.61%).

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

About CorMedix

CRMD stock →

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees

AQST vs CRMD FAQ

Which is bigger, Aquestive Therapeutics or CorMedix?

Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $419.16M for CorMedix (CRMD).

Which stock has performed better over the past year, AQST or CRMD?

AQST returned -39.51% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.

Are Aquestive Therapeutics and CorMedix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons